Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephane Hunot

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Annals of Neurology|April 1, 2003
Neuroinflammatory processes in Parkinson's diseaseStephane Hunot, E C Hirsch
The Lancet. Neurology|June 8, 2015
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerationsBenjamin Dehay, Mathieu Bourdenx, Philippe Gorry, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 18, 2008
Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's diseaseJulio Salazar, Natalia Mena, Stephane Hunot, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Annals of Neurology|April 1, 2003
Neuroinflammatory processes in Parkinson's diseaseStephane Hunot, E C Hirsch
The Lancet. Neurology|June 8, 2015
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerationsBenjamin Dehay, Mathieu Bourdenx, Philippe Gorry, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 18, 2008
Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's diseaseJulio Salazar, Natalia Mena, Stephane Hunot, et al.
Pageof 1